NWAM LLC’s Novavax NVAX Stock Holding History

NWAM LLC’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-600	Closed	-$15K	–	354
2017 Q4	$15K	Hold	600	–	–	﹤0.01%	323
2017 Q3	$14K	Hold	600	–	–	﹤0.01%	327
2017 Q2	$14K	Buy	+600	New	+$11.8K	﹤0.01%	322

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NWAM LLC's NVAX Position: Q1 2018 in Review

NWAM LLC sold out of Novavax (NVAX) in Q1 2018, closing a stake of 600 shares — an estimated $15K sold.

NWAM LLC first reported a position in NVAX in Q2 2017 and held it in 3 quarters. The position peaked at $15K in Q4 2017. 151 funds tracked by Wall St. Rank hold NVAX as of Q1 2018.

NWAM LLC reported no remaining Novavax position as of Q1 2018 after selling out during the quarter.
NWAM LLC sold 600 Novavax shares in Q1 2018, an estimated $15K.
NWAM LLC first reported a position in Novavax in Q2 2017 and held it in 3 quarters.
NWAM LLC's Novavax position peaked at $15K in Q4 2017.
151 funds tracked by Wall St. Rank held Novavax as of Q1 2018.

Based on NWAM LLC's 13F filing for Q1 2018, filed 16 Apr 2018.